[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.166.112.64. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Negative Results
July 6, 1964

ACTH for Ocular Myasthenia

Author Affiliations

Washington, DC

From the Special Projects Branch, National Institute of Neurological Diseases and Blindness.

JAMA. 1964;189(1):55. doi:10.1001/jama.1964.03070010061013
Abstract

A CAREFULLY CONDUCTED CLINICAL TRIAL is the most efficient means by which to determine the usefulness of a particular treatment in a particular disease. Sometimes a treatment is so obviously effective that a clinical trial serves primarily to establish its usefulness relative to other treatments and to the severity of disease. Often, however, the effectiveness of a treatment remains indecisive even after considerable use. This is partly because of the vagaries of the disease and partly because of the enthusiasms and expectations of both patient and doctor. In such a situation, a clinical trial offers a way to a valid decision concerning an agent's usefulness. Corticotropin (ACTH) and corticosteroids have been tried in the treatment of patients with myasthenia gravis, but estimates of their value were inconclusive.1 A group of clinical investigators, therefore, decided to undertake a controlled clinical trial to test the efficacy of a short course of ACTH

First Page Preview View Large
First page PDF preview
First page PDF preview
×